Ravi Shah, MD

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

The inhibition of Janus kinase to prevent downstream signaling of proinflammatory cytokines has been shown to be a novel method of treating ulcerative colitis.